Trial Profile
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 28 Feb 2019 Status changed from active, no longer recruiting to completed.
- 15 Dec 2017 Planned End Date changed from 1 Mar 2016 to 30 Mar 2018.
- 20 Apr 2015 Planned End Date changed from 1 Aug 2014 to 1 Mar 2016 as reported by ClinicalTrials.gov record.